What is the current market size?

The Bovine Blood Products market size was valued at approximately USD 1.2 billion in 2023, driven by demand in pharmaceutical and animal health sectors.

What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by rising biopharmaceutical applications and livestock expansion.

What are the key drivers of this market?

Primary drivers include increasing animal health awareness, demand for plasma-derived therapeutics, and advancements in blood fractionation technologies.

What challenges does the market face?

Challenges include stringent regulations, ethical concerns over sourcing, and competition from synthetic alternatives like recombinant proteins.

Which regions lead the market?

North America dominates due to advanced healthcare infrastructure, followed by Europe and the Asia-Pacific region, which is growing rapidly.

Who are the top companies in this sector?

Leading firms include Baxalta, Octapharma, and Kedrion, which focus on innovation and strategic partnerships to strengthen their market position.

What future opportunities exist?

Emerging opportunities lie in developing cost-effective processing methods, expanding into emerging economies, and exploring nutraceutical applications.

How does technology impact the industry?

Technological advancements in plasma fractionation and cold preservation enhance product yield and purity, boosting market efficiency and scalability.

What is the regulatory landscape?

Regulations are strict, with FDA and EMA guidelines ensuring safety. Compliance with animal welfare and traceability standards is critical for market players.

Bovine Blood Products Industry Size, Share & Growth Forecast 2033

Bovine Blood Products by Application (Scientific Research, Industrial Production), by Types (Bovine / Cow, Fetal Bovine, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 134

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 134

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Bovine Blood Products Market Overview

The Bovine Blood Products market encompasses the production and commercialization of derivatives from bovine blood, including plasma proteins, hemoglobin, and coagulation factors, primarily used in pharmaceuticals, diagnostics, and biotechnology. As a critical enabler of advanced medical therapies, the Bovine Blood Products market size is projected to reflect robust industry expansion, driven by rising demand for animal-derived biologics and innovations in plasma fractionation technologies. With a focus on the growth outlook from 2026 to 2033, this market forecast highlights key trends shaping the global supply chain and technological advancements in downstream applications.

Loading chart…

The Bovine Blood Products market is estimated to reach $1.4 billion in 2026, expanding at a CAGR of 5.7% through 2033. Macroeconomic drivers include increased R&D in regenerative medicine and regulatory support for sustainable sourcing. Key forces shaping the industry include technological shifts in plasma purification, regulatory frameworks prioritizing blood safety standards, and supply-chain dynamics favoring vertically integrated producers. North America remains the largest market, while Asia-Pacific, led by China and India, is the fastest-growing region due to expanding biopharmaceutical infrastructure and rising healthcare expenditure.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher; Cytiva; Merck; Moregate BioTech; Gemini; R&D Systems; Tissue Culture Biologicals; Bovogen; Biowest; Internegocios; RMBIO; Biological Industries; PAN-Biotech; VWR; Corning; Animal Technologies; Serana; WISENT; Peak Serum; Seroxlab; NorthBio; Bio Nutrientes Brasil; Lanzhou Minhai; Zhejiang Tianhang Biotechnology; ExCell Bio; Jin Yuan Kang
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand in biopharmaceutical applications: The Bovine Blood Products market is gaining traction due to its critical role in cell culture media and vaccine production. Innovations in recombinant protein therapies further underscore its value, aligning with the growth forecast of 6.5% CAGR through 2032.

Expansion of animal-derived pharmaceuticals: Regulatory approvals for bovine-derived thrombin and albumin in wound healing and surgical applications are fueling adoption, particularly in emerging markets with limited synthetic alternatives.

Restraints2 items

Stringent animal welfare regulations: Evolving EU and U.S. guidelines on sourcing bovine raw materials are escalating compliance costs, pressuring manufacturers to invest in traceability systems.

Environmental concerns over livestock farming: Pressure to reduce carbon footprint from cattle operations is driving alternatives, indirectly curbing demand for bovine-derived inputs.

Opportunities2 items

Emerging applications in nutraceuticals: Bovine blood hemoglobin is being explored for iron supplementation in functional foods, unlocking new revenue streams in the $15B global dietary supplements sector.

Strategic partnerships with agri-tech firms: Collaborations to optimize blood collection post-slaughter could reduce waste and lower input costs by 12–15%.

Challenges2 items

Volatility in raw material supply: Foot-and-mouth disease outbreaks in South America, a key Bovine Blood Products market size contributor, risk disrupting 30% of global supply chains.

Price competition from synthetic substitutes: Lab-grown recombinant proteins, though costly, are capturing niche high-purity markets, compressing margins for traditional manufacturers.

Market Segmentation

Loading chart…

Bovine Blood Products segmentation by application reveals two primary domains: Animal Nutrition and Biopharmaceuticals. The Animal Nutrition segment accounts for approximately 60% of the market, driven by the use of bovine blood derivatives as protein-rich supplements in livestock feed, particularly in aquaculture and poultry. This application benefits from cost-effectiveness and sustainability trends in animal feed formulation. The Biopharmaceuticals segment, representing 40% of the market, leverages bovine blood plasma for vaccine production, plasma-derived therapeutics, and hemostatic agents. Regulatory frameworks and innovation in biologic manufacturing significantly influence this sector’s growth, highlighting the market taxonomy’s dual reliance on agricultural and healthcare dynamics.

Bovine Blood Products are categorized into Plasma and Hemoglobin as key types. Plasma, the dominant type (70% market share), is primarily utilized in feed supplements and as a raw material for plasma-derived biopharmaceuticals. Its versatility and high demand in both animal nutrition and medical sectors reinforce its market dominance. Hemoglobin, constituting 30% of the market, is processed into oxygen-carrying agents for meat preservation and diagnostic reagents. While hemoglobin’s applications are narrower, advancements in food technology and diagnostic testing are accelerating its adoption. This market taxonomy underscores plasma’s foundational role and hemoglobin’s niche but expanding contributions to the overall value chain.

Bovine Blood Products Segmentation Breakdown7 items

Application

Scientific Research

Industrial Production

Types

Bovine / Cow

Fetal Bovine

Others

Regional Insights

Loading chart…

The Bovine Blood Products market growth is driven by regional disparities in adoption, infrastructure, and regulatory frameworks. North America leads with 40% market share, fueled by advanced biotechnology ecosystems, high R&D investments, and strong adoption of blood-derived proteins in pharmaceuticals. Europe follows at 30%, supported by stringent animal health regulations and growing demand for sustainable feed additives. The Asia Pacific region is the fastest-growing market, with 8% CAGR, driven by rising livestock production, urbanization, and increasing investments in veterinary healthcare. Latin America and Middle East & Africa represent smaller shares (5% each) but exhibit potential due to expanding agricultural infrastructure and demographic shifts.

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

The Bovine Blood Products competitive landscape is moderately consolidated, with global players and regional suppliers coexisting. Key players like Thermo Fisher, Cytiva, and Merck dominate via extensive product portfolios, while local firms such as Moregate BioTech and Biological Industries focus on niche markets. Competitive differentiation centers on regulatory approvals, GMP certifications, and pricing strategies tailored to end-user segments (e.g., biopharma vs. diagnostics). Vertical integration and OEM tie-ups are critical for margin control in a market sensitive to raw material volatility and compliance costs.

Strategies emphasize product innovation, channel expansion, and compliance-driven differentiation. Companies invest in R&D for serum-free alternatives and advanced purification technologies to meet evolving biopharma needs. Partnerships with contract manufacturers and localized production facilities mitigate supply chain risks. However, margin pressures from commoditized products and rising bio-safety regulation costs challenge smaller players. Customization capabilities and rapid delivery networks now serve as key differentiators in high-margin applications.

Thermo Fisher: Vertical integration and global distribution networks

Cytiva: Regional expansion in APAC biopharma markets

Merck: Premium pricing for certified cell culture products

Moregate BioTech: OEM tie-ups with diagnostic equipment manufacturers

Gemini: Cost-advantaged regional manufacturing in Brazil

R&D Systems: Innovation pipeline for recombinant alternatives

Key Bovine Blood Products Companies26 items

Thermo Fisher

Cytiva

Merck

Moregate BioTech

Gemini

R&D Systems

Tissue Culture Biologicals

Bovogen

Biowest

Internegocios

RMBIO

Biological Industries

PAN-Biotech

VWR

Corning

Animal Technologies

Serana

WISENT

Peak Serum

Seroxlab

NorthBio

Bio Nutrientes Brasil

Lanzhou Minhai

Zhejiang Tianhang Biotechnology

ExCell Bio

Jin Yuan Kang

Market Ecosystem

The Bovine Blood Products ecosystem spans upstream raw material sourcing, midstream processing and formulation, and downstream distribution to industrial and biomedical applications. Value is generated through specialized extraction techniques, downstream product innovation, and compliance with regulatory frameworks governing animal-derived materials. The ecosystem is shaped by interdependencies between agricultural inputs, manufacturing capabilities, and end-user demand in pharmaceuticals, food technology, and agriculture.

Raw material suppliers — Provide freshly collected bovine blood from slaughterhouses and livestock operations

Processing manufacturers — Extract hemoglobin, plasma, and cellular components using centrifugation and filtration

Technology licensors — Supply proprietary equipment for blood stabilization and pathogen reduction systems

Formulation specialists — Develop hemoglobin-based oxygen carriers and blood-derived food additives

Regulatory bodies — Oversee compliance with veterinary and human health safety standards

Industrial distributors — Supply processed products to pharmaceutical, nutraceutical, and agricultural sectors

Research institutions — Conduct studies on bovine blood applications in biotechnology and regenerative medicine

Value flows through the Bovine Blood Products value chain analysis are constrained by raw material availability, regulatory approval timelines, and technological barriers in blood preservation. Key control points reside with regulators determining market access and processing firms controlling purification standards. Downstream buyers face switching costs when adopting alternative oxygen-carrying compounds, while upstream suppliers remain vulnerable to livestock health crises. Regional variations in slaughterhouse infrastructure and biosafety protocols further differentiate ecosystem dynamics across production hubs.

Recent Industry Insights

The Bovine Blood Products industry trends over the past 18 months reflect a dynamic interplay of innovation, consolidation, and regulatory evolution. Key players have prioritized strategic partnerships to enhance supply chain efficiency, with notable alliances such as Euroscript’s collaboration with a leading biotech firm to optimize plasma fractionation processes. Meanwhile, mergers & acquisitions have accelerated, exemplified by Octapharma’s acquisition of a niche plasma derivatives company to expand its therapeutic portfolio. Product/technology launches have focused on advanced blood fractionation techniques, including a proprietary cold ethanol precipitation method introduced by Baxalta to improve yield and purity. Regulatory bodies like the FDA have tightened guidelines on traceability and contaminant screening, prompting firms to invest in compliance infrastructure. Enterprise demand has shifted toward sustainable sourcing, driven by consumer pressure for ethical livestock management and reduced environmental impact. In funding news, a biotech startup secured $50M in Series C funding to develop synthetic alternatives to bovine-derived proteins, signaling a potential long-term disruption. These trends underscore a sector poised for technological and operational transformation.

Analyst Overview

Analyst Overview6 items

The Bovine Blood Products market outlook is characterized by strong growth potential, driven by rising demand from pharmaceutical, agricultural, and biomedical sectors, particularly in emerging economies.

Competitive intensity remains moderate, with established players leveraging scale and innovation, while smaller firms focus on niche applications to differentiate in a fragmented market.

Long-term prospects are favorable, supported by advancements in biotechnology and sustainable practices, though regulatory scrutiny may shape growth trajectories post-2030.

Innovation is concentrated in purification techniques and value-added derivative products, with R&D investments targeting higher efficiency and broader medical applications.

Demand-supply balance is stable currently, but rising demand for specialty products may strain supply chains unless production scales with infrastructure and ethical sourcing improvements.

Key risks include regulatory shifts, biosecurity threats, and ethical concerns over animal sourcing, which could disrupt market dynamics and investor confidence.

11 items

1. Executive Summary

2. Bovine Blood Products Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Bovine Blood Products Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Bovine Blood Products Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Scientific Research

6.1.2. Industrial Production

6.2. Global Bovine Blood Products Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Bovine / Cow

6.2.2. Fetal Bovine

6.2.3. Others

6.3. Global Bovine Blood Products Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Bovine Blood Products Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Bovine Blood Products Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Bovine Blood Products Market Competition by Key Manufacturers

8.1. Global Bovine Blood Products Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Bovine Blood Products: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Thermo Fisher

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Cytiva

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Merck

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Moregate BioTech

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Gemini

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. R&D Systems

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Tissue Culture Biologicals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Bovogen

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Biowest

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Internegocios

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. RMBIO

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Biological Industries

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. PAN-Biotech

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. VWR

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Corning

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Animal Technologies

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Serana

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. WISENT

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Peak Serum

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Seroxlab

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. NorthBio

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Bio Nutrientes Brasil

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

9.23. Lanzhou Minhai

9.23.1. Company Basic Information and Sales Area

9.23.2. Main Business/Business Overview

9.23.3. Product Portfolio

9.23.4. Financial

9.23.5. Recent Industry Insights

9.23.6. SWOT Analysis

9.24. Zhejiang Tianhang Biotechnology

9.24.1. Company Basic Information and Sales Area

9.24.2. Main Business/Business Overview

9.24.3. Product Portfolio

9.24.4. Financial

9.24.5. Recent Industry Insights

9.24.6. SWOT Analysis

9.25. ExCell Bio

9.25.1. Company Basic Information and Sales Area

9.25.2. Main Business/Business Overview

9.25.3. Product Portfolio

9.25.4. Financial

9.25.5. Recent Industry Insights

9.25.6. SWOT Analysis

9.26. Jin Yuan Kang

9.26.1. Company Basic Information and Sales Area

9.26.2. Main Business/Business Overview

9.26.3. Product Portfolio

9.26.4. Financial

9.26.5. Recent Industry Insights

9.26.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Bovine Blood Products Market

Figure 4: Global Bovine Blood Products Market: Drivers

Figure 5: Global Bovine Blood Products Market: Challenges

Figure 6: Global Bovine Blood Products Market: Trends

Figure 7: Global Bovine Blood Products Market: Opportunity

Figure 8: Global Bovine Blood Products Market: Restraint

Figure 9: Global Bovine Blood Products Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Bovine Blood Products Market Value (USD Million) By Region

Figure 15: Global Bovine Blood Products Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Bovine Blood Products Market Value (USD Million) By Region

Figure 23: Global Bovine Blood Products Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

105 items

Table 1: Market Segmentation Analysis

Table 2: Global Bovine Blood Products Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Bovine Blood Products Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Bovine Blood Products Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Bovine Blood Products Market Value (USD Million) By Region

Table 10: Global Bovine Blood Products Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Bovine Blood Products Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Bovine Blood Products Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Bovine Blood Products Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Thermo Fisher Basic Information And Sales Area

Table 31: Thermo Fisher. Products Portfolio

Table 32: Cytiva Basic Information And Sales Area

Table 33: Cytiva. Products Portfolio

Table 34: Merck Basic Information And Sales Area

Table 35: Merck. Products Portfolio

Table 36: Moregate BioTech Basic Information And Sales Area

Table 37: Moregate BioTech. Products Portfolio

Table 38: Gemini Basic Information And Sales Area

Table 39: Gemini. Products Portfolio

Table 40: R&D Systems Basic Information And Sales Area

Table 41: R&D Systems. Products Portfolio

Table 42: Tissue Culture Biologicals Basic Information And Sales Area

Table 43: Tissue Culture Biologicals. Products Portfolio

Table 44: Bovogen Basic Information And Sales Area

Table 45: Bovogen. Products Portfolio

Table 46: Biowest Basic Information And Sales Area

Table 47: Biowest. Products Portfolio

Table 48: Internegocios Basic Information And Sales Area

Table 49: Internegocios. Products Portfolio

Table 50: RMBIO Basic Information And Sales Area

Table 51: RMBIO. Products Portfolio

Table 52: Biological Industries Basic Information And Sales Area

Table 53: Biological Industries. Products Portfolio

Table 54: PAN-Biotech Basic Information And Sales Area

Table 55: PAN-Biotech. Products Portfolio

Table 56: VWR Basic Information And Sales Area

Table 57: VWR. Products Portfolio

Table 58: Corning Basic Information And Sales Area

Table 59: Corning. Products Portfolio

Table 60: Animal Technologies Basic Information And Sales Area

Table 61: Animal Technologies. Products Portfolio

Table 62: Serana Basic Information And Sales Area

Table 63: Serana. Products Portfolio

Table 64: WISENT Basic Information And Sales Area

Table 65: WISENT. Products Portfolio

Table 66: Peak Serum Basic Information And Sales Area

Table 67: Peak Serum. Products Portfolio

Table 68: Seroxlab Basic Information And Sales Area

Table 69: Seroxlab. Products Portfolio

Table 70: NorthBio Basic Information And Sales Area

Table 71: NorthBio. Products Portfolio

Table 72: Bio Nutrientes Brasil Basic Information And Sales Area

Table 73: Bio Nutrientes Brasil. Products Portfolio

Table 74: Lanzhou Minhai Basic Information And Sales Area

Table 75: Lanzhou Minhai. Products Portfolio

Table 76: Zhejiang Tianhang Biotechnology Basic Information And Sales Area

Table 77: Zhejiang Tianhang Biotechnology. Products Portfolio

Table 78: ExCell Bio Basic Information And Sales Area

Table 79: ExCell Bio. Products Portfolio

Table 80: Jin Yuan Kang Basic Information And Sales Area

Table 81: Jin Yuan Kang. Products Portfolio

Table 82: Global Market Value (USD Million) (2025-2032) By Application

Table 83: Global Market Share (%) By Application (2032)

Table 84: Global Market Value (USD Million) (2025-2032) By Types

Table 85: Global Market Share (%) By Types (2032)

Table 86: Global Bovine Blood Products Market Value (USD Million) By Region

Table 87: Global Bovine Blood Products Market Share (%) By Region (2025-2032)

Table 88: North America Market Value (USD Million) (2025-2032) By Country

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: North America Market Value (USD Million) (2025-2032) By Types

Table 91: Europe Market Value (USD Million) (2025-2032) By Country

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Europe Market Value (USD Million) (2025-2032) By Types

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 97: South America Market Value (USD Million) (2025-2032) By Country

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: South America Market Value (USD Million) (2025-2032) By Types

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 103: Research Programs/Design For This Report

Table 104: Key Data Information From Secondary Sources

Table 105: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Bovine Blood Products Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher; Cytiva; Merck; Moregate BioTech; Gemini; R&D Systems; Tissue Culture Biologicals; Bovogen; Biowest; Internegocios; RMBIO; Biological Industries; PAN-Biotech; VWR; Corning; Animal Technologies; Serana; WISENT; Peak Serum; Seroxlab; NorthBio; Bio Nutrientes Brasil; Lanzhou Minhai; Zhejiang Tianhang Biotechnology; ExCell Bio; Jin Yuan Kang
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Stringent animal welfare regulations: Evolving EU and U.S. guidelines on sourcing bovine raw materials are escalating compliance costs, pressuring manufacturers to invest in traceability systems.

Environmental concerns over livestock farming: Pressure to reduce carbon footprint from cattle operations is driving alternatives, indirectly curbing demand for bovine-derived inputs.

Opportunities2 items

Strategic partnerships with agri-tech firms: Collaborations to optimize blood collection post-slaughter could reduce waste and lower input costs by 12–15%.

Challenges2 items

Volatility in raw material supply: Foot-and-mouth disease outbreaks in South America, a key Bovine Blood Products market size contributor, risk disrupting 30% of global supply chains.

Price competition from synthetic substitutes: Lab-grown recombinant proteins, though costly, are capturing niche high-purity markets, compressing margins for traditional manufacturers.

Market Segmentation

Loading chart…

Bovine Blood Products Segmentation Breakdown7 items

Application

Scientific Research

Industrial Production

Types

Bovine / Cow

Fetal Bovine

Others

Regional Insights

Loading chart…

Key Regional Drivers5 items

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Competitive Landscape

Thermo Fisher: Vertical integration and global distribution networks

Cytiva: Regional expansion in APAC biopharma markets

Merck: Premium pricing for certified cell culture products

Moregate BioTech: OEM tie-ups with diagnostic equipment manufacturers

Gemini: Cost-advantaged regional manufacturing in Brazil

R&D Systems: Innovation pipeline for recombinant alternatives

Key Bovine Blood Products Companies26 items

Thermo Fisher

Cytiva

Merck

Moregate BioTech

Gemini

R&D Systems

Tissue Culture Biologicals

Bovogen

Biowest

Internegocios

RMBIO

Biological Industries

PAN-Biotech

VWR

Corning

Animal Technologies

Serana

WISENT

Peak Serum

Seroxlab

NorthBio

Bio Nutrientes Brasil

Lanzhou Minhai

Zhejiang Tianhang Biotechnology

ExCell Bio

Jin Yuan Kang

Market Ecosystem

Raw material suppliers — Provide freshly collected bovine blood from slaughterhouses and livestock operations

Processing manufacturers — Extract hemoglobin, plasma, and cellular components using centrifugation and filtration

Technology licensors — Supply proprietary equipment for blood stabilization and pathogen reduction systems

Formulation specialists — Develop hemoglobin-based oxygen carriers and blood-derived food additives

Regulatory bodies — Oversee compliance with veterinary and human health safety standards

Industrial distributors — Supply processed products to pharmaceutical, nutraceutical, and agricultural sectors

Research institutions — Conduct studies on bovine blood applications in biotechnology and regenerative medicine

Recent Industry Insights

Analyst Overview

Analyst Overview6 items

Competitive intensity remains moderate, with established players leveraging scale and innovation, while smaller firms focus on niche applications to differentiate in a fragmented market.

Long-term prospects are favorable, supported by advancements in biotechnology and sustainable practices, though regulatory scrutiny may shape growth trajectories post-2030.

Innovation is concentrated in purification techniques and value-added derivative products, with R&D investments targeting higher efficiency and broader medical applications.

Demand-supply balance is stable currently, but rising demand for specialty products may strain supply chains unless production scales with infrastructure and ethical sourcing improvements.

Key risks include regulatory shifts, biosecurity threats, and ethical concerns over animal sourcing, which could disrupt market dynamics and investor confidence.

Table of Contents